Works matching IS 03407004 AND DT 2020 AND VI 69 AND IP 5
Results: 19
Talimogene laherparepvec treatment to overcome loco-regional acquired resistance to immune checkpoint blockade in tumor stage IIIB–IV M1c melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 759, doi. 10.1007/s00262-020-02487-x
- By:
- Publication type:
- Article
CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 825, doi. 10.1007/s00262-020-02486-y
- By:
- Publication type:
- Article
New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 867, doi. 10.1007/s00262-020-02484-0
- By:
- Publication type:
- Article
Long-term surviving cancer patients as a source of therapeutic TCR.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 859, doi. 10.1007/s00262-019-02468-9
- By:
- Publication type:
- Article
Current progress in NK cell biology and NK cell-based cancer immunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 879, doi. 10.1007/s00262-020-02532-9
- By:
- Publication type:
- Article
Significant association between tumor mutational burden and immune-related adverse events during immune checkpoint inhibition therapies.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 683, doi. 10.1007/s00262-020-02543-6
- By:
- Publication type:
- Article
Immunoregulatory effects of Lurbinectedin in chronic lymphocytic leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 813, doi. 10.1007/s00262-020-02513-y
- By:
- Publication type:
- Article
Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 799, doi. 10.1007/s00262-020-02512-z
- By:
- Publication type:
- Article
Human inflammatory dendritic cells in malignant pleural effusions induce Th1 cell differentiation.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 779, doi. 10.1007/s00262-020-02510-1
- By:
- Publication type:
- Article
LincRNA-p21 knockdown reversed tumor-associated macrophages function by promoting MDM2 to antagonize* p53 activation and alleviate breast cancer development.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 835, doi. 10.1007/s00262-020-02511-0
- By:
- Publication type:
- Article
Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 745, doi. 10.1007/s00262-020-02508-9
- By:
- Publication type:
- Article
Tumor mutational load, CD8+ T cells, expression of PD-L1 and HLA class I to guide immunotherapy decisions in NSCLC patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 771, doi. 10.1007/s00262-020-02506-x
- By:
- Publication type:
- Article
Nonlinear response to cancer nanotherapy due to macrophage interactions revealed by mathematical modeling and evaluated in a murine model via CRISPR-modulated macrophage polarization.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 731, doi. 10.1007/s00262-020-02504-z
- By:
- Publication type:
- Article
The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 703, doi. 10.1007/s00262-020-02503-0
- By:
- Publication type:
- Article
CD160 expression on CD8+ T cells is associated with active effector responses but limited activation potential in pancreatic cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 789, doi. 10.1007/s00262-020-02500-3
- By:
- Publication type:
- Article
Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 847, doi. 10.1007/s00262-020-02498-8
- By:
- Publication type:
- Article
Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 689, doi. 10.1007/s00262-020-02499-7
- By:
- Publication type:
- Article
Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 717, doi. 10.1007/s00262-020-02497-9
- By:
- Publication type:
- Article
"Tumor immunology meets oncology (TIMO) XV", April 25th–27th 2019, Halle/Saale, Germany.
- Published in:
- Cancer Immunology, Immunotherapy, 2020, v. 69, n. 5, p. 901, doi. 10.1007/s00262-020-02491-1
- By:
- Publication type:
- Article